Early use of vasopressin to prevent acute kidney injury in patients with septic shock.

vasopressin as an early adjunctive to prevent acute kidney injury in patients with septic shock: A randomized control study. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089568

Enrollment

Registered

2025-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I998- Other disorder of circulatory system

Interventions

Intervention1: Norepinephrine Plus Vasopressin: Eligible patients with septic shock will be identified and recruited from intensive care unit. After obtaining informed consent, patients will be random

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1 Age 18 years or more 2 Diagnosis of septic shock according to the Sepsis3 criteria 3 Requirement of vasopressor therapy to maintain MAP more than 65 mmHg despite adequate fluid resuscitation

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1. Lack Of Consent, 2. Known Cardiovascular Impairment [Cardiac Index (Ci) Less Than 2.2 L/Min/M2 ], 3. Unstable Coronary Artery Disease (Acute Angina or Myocardial Infarction In The Course Of Septic Shock, Based On History, Cardiac Biomarkers And Electrocardiogram), 4. Stroke Or Head Injury, 5. Chronic Renal Failure on Maintenance Dialysis, Advanced Stages Of Malignancy, 6. Acute Mesenteric Ischemia, 7. Raynaud s Disease, 8. Pregnant Women, 9. Patients With Transplanted Organs, And 10. Known Hypersensitivity To Norepinephrine Or Vasopressin.

Design outcomes

Primary

Measure	Time frame
Primary Outcome: 1. Incidence of renal failure, 2. Need for renal replacement therapy (RRT) 3. Changes in SOFA scores at 24 hours Timepoint: To compare the effectiveness of norepinephrine plus vasopressin versus norepinephrine alone to prevent acute renal failure in patients with septic shock.	—

Secondary

Measure	Time frame
Secondary Outcomes: 1. Total dose of norepinephrine required to achieve and maintain the target MAP 2. ICU and hospital length of stay. 3. Incidence of new organ dysfunction (SOFA score). 4. Adverse events related to vasopressor therapy (e.g., arrhythmias, ischemia). Timepoint: Total dose of norepinephrine required to achieve and maintain the target MAP in patients with septic shock.	—

Countries

India

Contacts

Public ContactDR RENUKA MK

sri ramachandra medical education and research

hod.criticalcare@sriramachandra.edu.in8056126336

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026